Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Not recruiting

Study on the Effectiveness and Safety of Lunsekimig (SAR443765) for Adults with Moderate to Severe Atopic Dermatitis

Fast replyInvestigationalNo placebo
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying atopic dermatitis, a condition that causes the skin to become red, itchy, and inflamed. The study will test a new treatment called lunsekimig (also known by its code name SAR443765), which is a type of protein designed to target specific parts of the immune system involved in causing the symptoms of atopic dermatitis. The trial will compare the effects of lunsekimig with a placebo to see how well it works and how safe it is for people with moderate to severe atopic dermatitis.

The purpose of the study is to evaluate how effective different doses of lunsekimig are in improving skin conditions in adults with moderate to severe atopic dermatitis. Participants in the study will receive one of three different doses of lunsekimig or a placebo, administered through an injection under the skin. The study will last for several months, during which participants will have regular check-ups to monitor their skin condition and overall health.

Throughout the study, researchers will assess changes in the severity of the skin condition using a tool called the Eczema Area and Severity Index (EASI). They will also look at other factors, such as the amount of skin affected by the condition and the impact on participants' quality of life. The study aims to provide valuable information on the potential benefits and safety of lunsekimig for treating atopic dermatitis.

The research process

The trial runs in 5 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Joining the study

    Upon joining the study, you will be randomly assigned to receive either the study medication, lunsekimig, or a placebo. A placebo is a substance with no active medication, used to compare the effects of the actual drug.

    The study is double-blind, meaning neither you nor the study staff will know which treatment you are receiving. This helps ensure the results are unbiased.

  2. Step 2

    Initial assessment

    At the beginning of the study, a detailed assessment of your skin condition will be conducted. This includes measuring the severity of your atopic dermatitis using the Eczema Area and Severity Index (EASI) score.

    You will also be asked to provide information about your symptoms, such as itching and skin pain, using numerical rating scales.

  3. Step 3

    Medication administration

    You will receive the study medication, lunsekimig, or placebo as a subcutaneous injection. This means the medication is injected under the skin.

    The study involves three different dosing regimens, but the specific dosage and frequency will be determined by the study protocol and assigned randomly.

  4. Step 4

    Ongoing assessments

    Throughout the study, regular assessments will be conducted to monitor your skin condition and overall health. This includes repeating the EASI score and other symptom ratings.

    These assessments will help track any changes in your condition and the effectiveness of the treatment.

  5. Step 5

    End of study evaluation

    At the end of the study, a final evaluation will be conducted to assess the overall impact of the treatment on your atopic dermatitis.

    This includes a final EASI score and other relevant measurements to determine the effectiveness and safety of the treatment.

Who can join the trial?

8 criteria

  • Participants must be between 18 and 80 years old.
  • Must have been diagnosed with Atopic Dermatitis (AD) for at least 1 year. Atopic Dermatitis is a condition that makes your skin red and itchy.
  • Must have a history within the last 6 months of either not responding well to or being advised against using creams or ointments applied to the skin.
  • Must have an Eczema Area and Severity Index (EASI) score of 16 or higher. This score measures the extent and severity of eczema, ranging from 0 to 72.
  • Must have a Validated Investigator Global Assessment Scale for Atopic Dermatitis (vIGA-AD) score of 3 or 4. This scale ranges from 0 to 4, where 3 means moderate and 4 means severe.
  • Must have eczema covering 10% or more of the body.
  • Must have a weekly average itch score of 4 or higher on a scale from 0 to 10.
  • Must have used a simple moisturizer without additives at least once daily for at least 5 out of 7 days before starting the study.

Who cannot join the trial?

9 criteria

  • Participants cannot have any other skin conditions that might interfere with the study.
  • Participants must not have used any other treatments for atopic dermatitis within a certain period before the study.
  • Participants should not have any serious health conditions that could affect their safety during the study.
  • Participants must not be pregnant or breastfeeding.
  • Participants should not have a history of allergic reactions to the study medication or similar medications.
  • Participants must not have participated in another clinical trial recently.
  • Participants should not have any infections that are not well controlled.
  • Participants must not have a history of drug or alcohol abuse.
  • Participants should not have any mental health conditions that might affect their ability to participate in the study.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

Lunsekimig (SAR443765) is a medication being studied for its potential to help people with moderate-to-severe atopic dermatitis, which is a type of skin condition that causes red, itchy, and inflamed skin. This medication is given as an injection under the skin. The goal of using lunsekimig in this study is to see if it can reduce the severity of skin lesions, which are areas of damaged skin, by improving the Eczema Area and Severity Index (EASI) score. This score is a way to measure how severe the eczema is and how much of the body it affects. By participating in this study, researchers hope to find out if lunsekimig can be an effective treatment option for people suffering from this skin condition.

What is already known about the treatment

Lunsekimig – Lunsekimig is administered through subcutaneous injections, meaning it is given as an injection under the skin. It is currently being studied in clinical trials for its effectiveness and safety in treating moderate-to-severe atopic dermatitis, a type of eczema. The main goal of this medication is to reduce skin lesions and improve the severity of eczema symptoms. At the molecular level, lunsekimig works by targeting specific pathways in the immune system that are involved in the inflammation and irritation seen in atopic dermatitis. It is classified as an immunomodulatory agent, which means it helps to regulate the immune system's response.

Investigated diseases

Atopic Dermatitis – Atopic dermatitis is a chronic inflammatory skin condition characterized by itchy, red, and swollen skin. It often begins in childhood but can occur at any age. The disease progresses through periods of flare-ups and remissions, where symptoms can worsen or improve. During flare-ups, affected areas may become dry, cracked, and prone to infection. The condition is associated with a compromised skin barrier, leading to increased sensitivity to irritants and allergens. Over time, repeated scratching can cause thickening of the skin and further irritation.
Trial detailsLast updated 2 Oct 2026
Age18+ yearsPhasePhase IITrial ID2024-511549-20-00Protocol codeDRI18252Estimated enrolment220 patientsSponsorSanofi-Aventis Recherche & Developpement

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

ClinicalTrials.eu

Every clinical trial in Europe, in plain language.

Explore the full ecosystem of clinical research in Europe.

Search trials

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).